OmniAb reported higher third-quarter revenue, citing increased service work and sales of instruments and related consumables. The antibody-discovery technology company also raised its full-year 2026 revenue and cash outlook, pointing to continued business momentum and progress across partnered programs.
The quarter’s revenue growth came alongside unchanged total costs and operating expenses of $20.4 million. OmniAb highlighted the expanded commercial launch of xPloration and the introduction of OmniTides as part of its efforts to grow its technology offerings.
Key details
- Revenue rose to $4.0 million in the three months ended Sept. 30, 2026, from $2.2 million a year earlier.
- Service revenue increased, primarily because of more work on antibody and ion-channel programs.
-
xPloration revenue grew on higher instrument sales and related consumables.
-
xPloration costs increased with sales. The cost of that revenue was $0.3 million, compared with $0.03 million in the year-earlier quarter, reflecting increased instrument and consumable sales.
-
Research and development expense declined to $9.6 million from $10.4 million. OmniAb attributed the decrease to lower personnel costs, including share-based compensation and salaries, as well as lower facility costs.
-
General and administrative expense rose to $7.2 million from $6.8 million. Higher external expenses, including legal and other public-company costs, were partly offset by lower personnel expense related to share-based compensation.
-
Total costs and operating expenses were $20.4 million, unchanged from the third quarter of 2025. Cash costs and operating expenses, a separate measure reported by the company, increased to $13.7 million from $12.3 million.
-
Amortization of intangibles edged down to $3.1 million from $3.2 million. Other operating expense was $0.2 million, compared with a small operating benefit in the year-earlier quarter; the change primarily reflected adjustments to contingent liabilities tied to certain ion-channel programs.
-
OmniAb raised its full-year 2026 revenue and cash outlook. The company said the increase reflected its performance to date and expectations for the rest of the year. The announcement also pointed to continued progress in programs that may generate milestones and royalties.
-
Product and portfolio developments: OmniAb cited the expanded commercial launch of xPloration and the introduction of OmniTides, alongside ongoing progress in its partnered programs.